Ovarian cancer, cervical cancer, fallopian tube cancer, primary peritoneal adenocarcinoma and other gynecological tumors
Conditions
Interventions
Observation group:None
Sponsors
Henan Provincial Cancer Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. July 1, 2022 ~ January 31, 2024; 2. Gynecological tumors such as cervical cancer, ovarian cancer, fallopian tube cancer, and primary peritoneal adenocarcinoma confirmed by imaging or histological pathological examination; Bevacizumab is indicated according to clinical diagnosis and treatment routine; 3. ECOG score of 0-1; 4. Receiving bevacizumab combination therapy (including chemotherapy, chemoradiotherapy, etc.).
Exclusion criteria
Exclusion criteria: 1. Other malignant tumors that are not gynecological tumors such as cervical cancer, ovarian cancer, fallopian tube cancer, and primary peritoneal adenocarcinoma; 2. Incomplete clinical case data (lack of efficacy evaluation information, adverse reaction evaluation information).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The number and proportion of users of bevacizumab combined with chemotherapy or radiotherapy;Objective response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Type and severity of adverse reactions;Incidence of adverse reactions; | — |
Countries
China
Contacts
Public ContactChao Hongtu
HenanCancerHospital
Outcome results
None listed